Clinical trials: Protease Inhibitor
HIV Infections
Effectiveness of Anti-HIV Drugs in Patients Who Have Not Received Previous Anti-HIV Drugs During Different Stages of HIV Infection
The purpose of this study is to compare changes in HIV levels and certain immune cells among patients at different stages of HIV infection.
- Trial name
- NCT00006443
- Testing
- Indinavir sulfate, Nelfinavir mesylate, Lamivudine
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Malaria, HIV Infections
HIV Protease Inhibitors for the Prevention of Malaria in Ugandan Children
HIV and malaria are major causes of morbidity and mortality in Sub-Saharan Africa and children bear the greatest brunt of both diseases. No single existing intervention is likely to control malaria in Africa.
- Trial name
- PROMOTE-PEDS (NCT00978068)
- Testing
- Lopinavir/Ritonavir (LPV/r), Nevirapine (NVP), Efavirenz (EFV)
- Where
- Uganda
- Volunteers
- 176 people, healthy volunteers welcome
- Sponsor
- University of California, San Francisco
HIV Infections
Ritonavir and Agenerase Treatment for Patients Who Have Failed Previous Anti-HIV Treatment
The purpose of this study is to determine if treatment with an anti-HIV drug containing ritonavir and Agenerase is safe and can lower the level of HIV in the blood in patients who have failed an anti-HIV drug treatment containing…
- Trial name
- NCT00006591
- Testing
- Ritonavir, Amprenavir
- Where
- United States
- Sponsor
- Gathe, Joseph, M.D.
HIV Infections
Comparison of GW433908/Ritonavir to Nelfinavir When Used With Abacavir and Lamivudine in Patients That Have Not Taken Antiretroviral Drugs
The purpose of this study is to compare virus response to GW433908/ritonavir (RTV) to viral response to nelfinavir (NFV) when used with abacavir (ABC)/lamivudine (3TC) in patients that have not taken antiretroviral (ART) drugs.
- Trial name
- NCT00009061
- Testing
- Ritonavir, Abacavir sulfate, Nelfinavir mesylate
- Where
- 37 sites in United States
- Volunteers
- 624 people
- Sponsor
- Glaxo Wellcome
HIV Infections, Hemophilia A
Effect of Indinavir Plus Two Other Anti-HIV Drugs on Blood Clotting in HIV-Positive Males With Hemophilia
The purpose of this study is to see if indinavir plus two other anti-HIV drugs affect blood clotting in HIV-positive patients with hemophilia.
- Trial name
- NCT00002386
- Testing
- Indinavir sulfate, Lamivudine, Stavudine
- Where
- 8 sites in United States, Canada
- Volunteers
- 55 people
- Sponsor
- Merck Sharp & Dohme LLC
HIV Infections
The Effectiveness of Indinavir Plus Zidovudine Plus Lamivudine in HIV-Infected Patients With No Symptoms of Infection
To evaluate the ability of the combination of indinavir, zidovudine, and lamivudine to suppress HIV-1 infection as measured by: (1) the maintenance of HIV-1 serum viral RNA below the limit of detection of the most sensitive…
- Trial name
- NCT00002179
- Testing
- Indinavir sulfate, Lamivudine, Zidovudine
- Where
- 17 sites in United States, Canada
- Volunteers
- 200 people
- Sponsor
- Merck Sharp & Dohme LLC
Coronavirus Disease 2019, Coronavirus Disease 2019 (COVID-19)
A Study of How Ibuzatrelvir is Taken up Into the Blood of Healthy Adults After Taking Different Tablets of Ibuzatrelvir
Healthy adults will be enrolled into this open-label, Phase 1 research study. Participants will spend about 9 nights and 10 days in the clinical research unit (CRU) and the total time in the study will be about 11 weeks.
- Conditions
- Coronavirus Disease 2019, Coronavirus Disease 2019 (COVID-19), COVID-19 (Coronavirus Disease 2019), Upper Respiratory Tract Infections
- Trial name
- NCT07552779
- Testing
- Ibuzatrelvir co-process API film coated tablet, Ibuzatrelvir filmcoated tablet
- Where
- Belgium
- Volunteers
- 17 people, healthy volunteers welcome
- Sponsor
- Pfizer
Hepatitis C
Outcome of New Direct Acting Agents For Hepatitis C A Community Based Experience
Chronic Hepatitis C virus (HCV) infection is the leading cause of advanced liver disease worldwide. The virus successfully evades host immune detection and has highly restricted requirements for growth in vitro that for many…
- Trial name
- NCT02485262
- Testing
- Sofosbuvir and simeprevir
- Where
- United States
- Volunteers
- 340 people
- Sponsor
- Arrowhead Regional Medical Center
Glioma
A Trial of the Protease Inhibitor Nelfinavir and Concurrent Radiation and Temozolomide in Patients With WHO Grade IV Glioma
This phase I trial will determine safety, dose-limiting toxicities (DLT) and maximum tolerable dose (MTD) of the protease inhibitor, Nelfinavir (NFV), when given with chemoradiotherapy as post-operative therapy for glioblastoma…
- Trial name
- NCT01020292
- Testing
- Nelfinavir
- Where
- United States
- Volunteers
- 31 people
- Sponsor
- Abramson Cancer Center at Penn Medicine
Hepatitis C
Efficacy and Safety of MP-424/Peginterferon Alfa-2b/Ribavirin Combination in Treatment-Naïve Patients With Chronic Hepatitis C
This study will evaluate the efficacy and safety of MP-424 with Peginterferon Alfa-2b (PEG-IFN) and Ribavirin (RBV) in treatment-naïve patients with (Genotype 1) hepatitis C.
- Trial name
- NCT00780416
- Testing
- MP-424, Ribavirin, Peginterferon Alfa-2b
- Where
- Japan
- Volunteers
- 189 people
- Sponsor
- Tanabe Pharma Corporation
HIV Infections
The Safety and Effectiveness of Saquinavir Soft Gelatin Capsules Combined With Other Anti-HIV Drugs
To evaluate the safety and antiretroviral activity of saquinavir soft gelatin capsule formulation (SQV-SGC) in combination with other antiretroviral drugs.
- Trial name
- NCT00002425
- Testing
- Saquinavir
- Where
- United States
- Volunteers
- 400 people
- Sponsor
- Hoffmann-La Roche
Alpha1-Antitrypsin Deficiency
Long-term Safety of Alpha1-Proteinase Inhibitor (Human) in Japanese Subjects With Alpha1 Antitrypsin Deficiency (GTI1401-OLE)
This is a multi-center, open-label study to evaluate the long-term safety of weekly intravenous (IV) infusions of 60 mg/kg alpha1-PI (human), modified process (Alpha-1 MP) in adult participants with Alpha1 Antitrypsin Deficiency…
- Trial name
- NCT02870348
- Testing
- Alpha-1 MP
- Where
- 3 sites in Japan
- Volunteers
- 4 people
- Sponsor
- Grifols Therapeutics LLC
HIV Infections
A Study on the Safety and Effectiveness of L-756423 Plus Indinavir in HIV-Positive Patients Who Have Previously Taken Indinavir
The purpose of this study is to see if L-756423, an anti-HIV drug, is safe to give with indinavir and if it works well at lowering the level of HIV in the blood (viral load).
- Trial name
- NCT00002452
- Testing
- L-756423, Indinavir sulfate
- Where
- 8 sites in United States
- Volunteers
- 30 people
- Sponsor
- Merck Sharp & Dohme LLC
HIV Infections
A Study to Compare Anti-HIV Drugs Given Twice a Day or Once a Day, With or Without Direct Observation
Anti-HIV drug therapy works best when the drugs are taken exactly as prescribed by a doctor. Because anti-HIV therapy often involves multiple drugs, some people have difficulty taking them all correctly.
- Trial name
- NCT00036452
- Testing
- lopinavir/ritonavir, emtricitabine, stavudine
- Where
- 29 sites in United States, Puerto Rico and 1 more
- Volunteers
- 402 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV Infections
A Study of Saquinavir and Zalcitabine, Used Alone and Together, in the Treatment of Advanced HIV Infection in Patients Who Stopped Taking or Who Cannot Take Zidovudine
To compare the safety, tolerance, and efficacy of saquinavir mesylate (Ro 31-8959) alone, zalcitabine (dideoxycytidine; ddC) alone, and both in combination, in patients discontinuing or unable to take zidovudine (AZT).
- Trial name
- NCT00002333
- Testing
- Saquinavir, Zalcitabine
- Where
- 47 sites in United States, Canada and 1 more
- Volunteers
- 900 people
- Sponsor
- Hoffmann-La Roche
HIV Infections
A Study of Several Anti-HIV Drug Combinations in HIV-Infected Patients Who Have Used Indinavir
To compare the proportion of patients whose plasma HIV-1 RNA is below 500 copies/ml after 16 weeks of treatment. To assess the safety, toxicity, and tolerance of each treatment arm.
- Trial name
- NCT00000892
- Testing
- Ritonavir, Nelfinavir mesylate, Levocarnitine
- Where
- 45 sites in United States
- Volunteers
- 300 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV Infections
Five-Drug Anti-HIV Treatment Followed by Treatment Interruption in Patients Who Have Recently Been Infected With HIV
This study will determine what effect taking a combination of five anti-HIV drugs during the early stage of HIV infection, then temporarily stopping them once or twice, may have on the amount of HIV virus in the blood (viral…
- Trial name
- NCT00000940
- Testing
- Ritonavir, Abacavir sulfate, Amprenavir
- Where
- 18 sites in United States
- Volunteers
- 121 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV Infections
A Phase I Randomized Dose/Formulation Comparison Study of SC-52151
PRIMARY: To evaluate the safety, tolerability, pharmacokinetics, and ethanol exposure of two dose regimens and formulations of SC-52151.
- Trial name
- NCT00000806
- Testing
- Telinavir
- Where
- 4 sites in United States
- Volunteers
- 48 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV Infections
A Study of Delavirdine Used Together With Other Anti-HIV Drugs in HIV-Infected Patients
The purpose of this study is to see if it is safe and effective to give delavirdine (DLV) in combination with two or three other drugs to HIV-infected patients.
- Trial name
- NCT00002401
- Testing
- Indinavir sulfate, Delavirdine mesylate, Lamivudine
- Where
- United States
- Volunteers
- 160 people
- Sponsor
- Pharmacia and Upjohn
Hepatitis C Virus
TMC435-TiDP16-C113: A Study to Investigate the Effect of Hepatic Impairment on the Pharmacokinetics of TMC435
The purpose of the study is to investigate the effect of moderate and severe hepatic impairment on the pharmacokinetics of TMC435.
- Trial name
- NCT01046058
- Testing
- TMC435
- Where
- 3 sites in United States
- Volunteers
- 23 people, healthy volunteers welcome
- Sponsor
- Tibotec Pharmaceuticals, Ireland